Technology

The update introduces a 250 kHz scan speed for OCT Angiography combined with enhanced TruTrack Active Eye Tracking, as well as new multimodal imaging capabilities, including the Green Autofluorescence Module

Alkeus Pharmaceuticals has dosed the first participant in the phase 3 NORTHSTAR trial of oral gildeuretinol for Stargardt disease, a condition with no approved treatments.

Finding satisfaction in ocular research—considerations about AI and enhanced datasets.

A newly developed diagnostic system, CaptureTumor (CaT), driven by artificial intelligence (AI) and designed specifically for smartphone deployment, achieved diagnostic accuracy comparable to that of a specialist-graded slit-lamp evaluation” for detecting rare ocular surface malignancies.

The device, described in a new study, uses a technique called temporal interference-based transcorneal electrical stimulation, or TI-TES.

The app is designed to improve confidence among neurology and ophthalmology trainees.

Wireless brain implant taps visual cortex to deliver artificial sight, marking third successful surgery and recruiting volunteers for trials.

In addition to ChatGPT for Clinicians, OpenAI introduced ChatGPT for Healthcare earlier this year.

Key regulatory filings, phase 3 readouts, and trial enrollments to watch through June 30.

Caution advised by doctors and aviation safety experts

Gene and cell therapies plus AI imaging tools accelerate breakthroughs for rare retinal diseases, spotlighting new trials for RP and Stargardt patients.

The clinical study will evaluate a noninvasive corneal strengthening procedure designed to reshape the cornea and correct refractive errors in-office without tissue removal.

Interventional therapies give patients faster relief and better vision outcomes

Steffen Schmitz-Valckenberg, MD, discusses how optical coherence tomography-based models may enable rapid, noninvasive assessment of functional loss in GA at Angiogenesis 2026.

Daniela Ferrara, MD, PhD, FASRS, FARVO, discusses how data from low- and middle-income countries can strengthen US trials, improve equity, and inform innovation as the field looks toward 2026.

Across sessions, speakers emphasized that AI is not a replacement for physician judgment.

P. Dee G. Stephenson, MD, FACS, shares insights on evolving LAL technology and best practices for managing the ocular surface before and after surgery.

Optometrists track 2026 breakthroughs in dry eye therapies, AI-powered screening and referrals, and genetics-driven glaucoma risk tools that reshape patient care.

As Glaucoma Awareness Month highlights evolving practice, specialists describe how artificial intelligence, sustained drug delivery, laser therapy, and workflow integration are reshaping earlier, more individualized glaucoma care.

Joel S. Schuman, MD, FACS, highlights home tonometry, virtual visual fields, and portable OCT devices as promising tools, while noting concerns around data reliability, patient adherence, and reimbursement.

Concentric lens positioning of an adjustable lens helps avoid a late myopic shift.

The year introduced shifts in residency education, and program directors reflect on changes, challenges, and what’s next.

The novel system converts light into electrical signals to stimulate retinal cells.

From artificial intelligence to home monitoring, Joel Schuman, MD, of Wills Eye Hospital, explores the innovations that could change how clinicians detect and treat glaucoma in the new year.